About Malecare

Malecare is the world's leading men's cancer support and advocacy nonprofit organization.

Tell the World About Malecare and Improve Our Exposure

Dear Friends, If you love the work of Malecare Cancer Support, then tell the world! You may or may not realize it, but Malecare has grown to become America's largest men's cancer survivor support and advocacy national nonprofit. Malecare is a 13-year-old all volunteer organization, and our mission is to help men and their families [...]

A Note from Chuck- An Expansion of Naval Vessels with Agent Orange Exposure Making VA Benefits Available to Additional Men

The Naval Fleet Reserve Association recently provided the following information regarding updates of the Veterans Administration list of vessels exposed to Agent Orange during the Vietnam conflict. This will include many more veterans eligible for VA care for the many diseases attributed to this product. […]

Study Finds that Degarelix is Superior to Leuprolide

According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]

FDA: 5-Alpha-Reductase Inhibitors May Increase High-Grade Prostate Cancer Risk

There is a constant debate between both oncologist and advocates about the value and safety of 5-alpha-reductase inhibitors (Proscar and Avodart) both in the early treatment and later treatment of men with prostate cancer. In fact, I have had an on-going private debate with one very knowledgeable educator advocate over this issue. I often have [...]

ASCO 2011: Phase II Cabozantinib Trial in Patients with Advanced Solid Tumors and Bone Metastases

Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]

My Friend Fred

My very dear friend Fred who is a 20+ year prostate cancer warrior recorded this video. He has been on chemotherapy this past year. Fred is an activist who has been fighting on behalf of all of us. Thank you, Fred. I just thought I would share his video at: See my friend Fred Joel [...]

Protect the Department of Defense CDMRP Prostate Cancer Research Program (DoD PCRP)

YOUR DEADLINE: WEDNESDAY, JUNE 22, 2011 On Wednesday and Thursday, the House will meet at 10:00 a.m. for Morning Hour debate and 12:00 p.m. for legislative business. H.R. 2219, the Department of Defense Appropriations Act, 2012 (Rep. Young (FL) - Appropriations), has been placed on the House calendar for then. As part of H.R. 2219 [...]

Update on Potential DOD Funding for the Prostate Cancer Program

From Anthony Hardie, Madison, Wis. All: I've just gone through the full Defense Committee bill (before yesterday's markup) and the corresponding report language on the various CDMRP programs. The results are below. FY12 Defense Appropriations -- Full Committee Bill (before yesterday's markup): 1. Several programs would not be funded at all: most notably the sort [...]

Combining and Sequencing the New Prostate Cancer Drugs, Can It Improve Treatment Outcomes? – On the Horizon

There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]

Three New Clinical Trials of Provenge At Earlier Stages

In anticipation of our Monday night teleconference on Provenge (see below for registration procedures) I am very happy to report that Dendreon is now detailing plans to move Provenge to earlier stages in the disease’s progress. At the American Society of Clinical Oncology (ASCO) meeting in Chicago which is winding down today, Dendreon unveiled plans [...]

Go to Top